Neurocrine Biosciences, Inc.

NASDAQ:NBIX

Biotechnology

Healthcare
$162.86 -0.45%

-$0.71 today

Market cap
$16.48B
Beta
0.40
P/E (TTM)
23.8
EPS (TTM)
$6.65
52W Low $122.14High $169.57

Volume 1.60M

Average 1.18M

NBIX Net Income

Bottom-line profit, the starting point for calculating cash from operations.

Neurocrine Biosciences, Inc.NASDAQ: NBIX

Net Income · Q3 FY2026 · quarter ended Sep 2026

Net income dips below year-ago levels

Q3 FY2026 net income of $206.5M fell 1.4% year over year, behind the +64.1% change in trailing-twelve-month net income. Sequentially, it rose 43.0% from the prior quarter. Over 3 fiscal years it compounded at +45.8% a year.

Context

  • Net income amounted to 16.7% of revenue in FY2025, up 2.2 pp from a year earlier.
  • Net income increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether net income reaches the consensus estimate from 18 analysts of $749.06M (+56.5%) for the fiscal year ending Dec 2026, a step up from the +40.2% reported in FY2025.

Sources:Cash Flow Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterSep 2026
$206.5M+43.0% QoQ
Last fiscal yearDec 2025
$478.6M+40.2% YoY
LTMSep 2026
$702.5M+64.1% YoY
Net Income past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-1.4%+41.4%+42.8 pp
1 year+40.2%+56.5%+16.3 pp
3-year CAGR+45.8%+51.0%+5.2 pp
5-year CAGR+23.8%—
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Net Income history

USD · from the cash flow

Latest · FY2025
478.6M USD
Year-over-year change
+40.2%
4-year CAGR
+52.0%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Net Income vs competitors

How NBIX compares with its peers on the latest reported figures

  • NBIX's LTM Sep 2026 net income of $702.5M is the 2nd largest of the 10 companies compared; the peer median is $191.64M.
  • Its year-over-year change of +64.1% is the 4th highest of 10, against a peer median of +34.0%.
  • Net income amounts to 19.0% of revenue for NBIX, versus a peer median of 29.2%.
NBIX Competitors Peer median
Net Income for NBIX and competitors
Company Period LTM YoY 3-year CAGR% of revenue
JAZZJazz Pharmaceuticals plcLTM Sep 2026$901.05M +144.5%+16.7%19.1%
NBIXNeurocrine Biosciences, Inc.LTM Sep 2026$702.5M +64.1%+45.8%19.0%
BHVNBiohaven Ltd.LTM Jun 2026$586.84M -23.5%+9.0%—
ACADACADIA Pharmaceuticals Inc.LTM Jun 2026$384.12M +72.9%—33.7%
VNDAVanda Pharmaceuticals Inc.LTM Mar 2026$239.55M +441.4%—110.0%
NMRANeumora Therapeutics, Inc. Common StockLTM Mar 2026$222.39M -13.8%+21.9%—
AXSMAxsome Therapeutics, Inc.LTM Jun 2026$191.64M -22.4%-0.7%24.7%
SUPNSupernus Pharmaceuticals, Inc.LTM Jun 2026$144.33M -323.8%—17.4%
RAPPRapport Therapeutics, Inc. Common StockLTM Mar 2026$107.28M +34.6%+118.7%536.4%
GHRSGH Research PLCLTM Mar 2026$56.41M +34.0%+29.0%—
Peer median (excluding NBIX) $191.64M+34.0%+19.3%29.2%

Competitors are the stored peer set for NBIX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income89.6M154.5M249.7M341.3M478.6M
Depreciation & Amortization10.9M15.6M21.3M27.1M30.1M
Deferred Income Tax4.3M19.1M(56.7M)(123.1M)165.4M
Stock-Based Compensation134.2M173.1M194.3M195.5M217.9M
Change in Working Capital16.7M(67.4M)28.2M(19.2M)(128.8M)
Accounts Receivables(28.4M)(162.2M)(89.3M)(39.8M)(210.5M)
Inventory(2.5M)(2.6M)5.4M(19.1M)(15.3M)
Accounts Payables00000
Other Working Capital47.6M97.4M112.1M39.7M97M
Other Non-Cash Items800K44.5M(46.9M)173.8M19.5M
Operating Cash Flow256.5M339.4M389.9M595.4M782.7M
Capital Expenditures(23.4M)(16.5M)(28.3M)(38.2M)(34M)
Acquisitions (Net)0(42.7M)000
Purchases of Investments(804.7M)(628.9M)(1.41B)(1.06B)(1.32B)
Sales of Investments697.9M511M972.4M967.5M1.09B
Other Investing Activities00000
Investing Cash Flow(130.2M)(177.1M)(467.1M)(126.8M)(264.4M)
Debt Repayment(100K)(279M)0(308.8M)0
Common Stock Issued27.5M44.7M65.3M122.1M129.4M
Common Stock Repurchased000(300M)(167.7M)
Dividends Paid00000
Other Financing Activities00000
Financing Cash Flow27.4M(234.3M)65.3M(486.7M)(38.3M)
Effect of Forex Changes0(1.3M)300K00
Net Change in Cash153.7M(73.3M)(11.6M)(18.1M)480M
Free Cash Flow233.1M322.9M361.6M557.2M748.7M

Neurocrine Biosciences, Inc.

NASDAQ:NBIX

Intrinsic Alpha fair value

Locked

Current Price

$162.86

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.